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Background: Toll-like receptors (TLRs) play a fundamental 
role in innate immunity through their capacity to recognize 
pathogen-associated molecular patterns. Also, TLRs that are 
expressed in T cells are reported to function as co-stim-
ulatory receptors. However, the functional capacity of TLRs 
on CD4 T and CD8 T cells has not been directly compared. 
Here we compared CD4 and CD8 T cell responses to TLR2 
ligand plus TCR-mediated stimulation. Methods: TLR2 ex-
pression was analyzed on T cell subsets under naïve and al-
loantigen-primed conditions. We analyzed the effects of 
TLR2 co-stimulation on proliferation and survival of T cell 
subsets in vitro when stimulated with soluble anti-CD3 in the 
presence or absence of synthetic ligand Pam3CSK4. Results: 
TLR2 expression on CD8 T cells was induced following acti-
vation; this expression was much higher than on CD4 T cells. 
Thus, the molecule was constitutively expressed on Listeria- 
specific memory CD8 T cells. Based on these expression lev-
els, proliferation and survival were markedly elevated in CD8 
T cells in response to the TLR2 co-stimulation by Pam3CSK4 
compared with those in CD4 T cells. Conclusion: Our data 
show that TLR2 co-stimulation is more responsible for pro-
liferation and survival of CD8 T cells than for that of CD4 T 
cells.
[Immune Network 2009;9(4):127-132]
INTRODUCTION
Toll-like receptors (TLRs) are primary sensor molecules that 
play an integral role in innate immunity via their capacity to 
recognize pathogen-associated molecular patterns that allow 
the detection of infection and inflammation (1). TLR stimula-
tion of dendritic cells (DCs) and macrophages promotes the 
production of pro-inflammatory cytokines and the up-regula-
tion of MHC and co-stimulatory molecules, which leads to the 
induction of T cell-mediated adaptive immune responses (2).
    Although much of our knowledge of TLR function in the 
immune system comes from the study of innate immune cells, 
these molecules also are expressed in T cells. Early studies 
of TLRs in T cells have been conducted with CD4 T cells. 
Naïv e  h u m a n  C D 4  T  c e l l s  e x p r e s s  T L R 2  a f t e r  a c t i v a t i o n  b y 
TCR  stimulation  and  TLR2  functions  as  a  co-stimulatory 
receptor. Moreover, TLR2 also participates in the generation 
and maintenance of CD4 T cell memory (3). TLR3 and TLR9 
ligand directly deregulate Bcl-xL in CD4 T cells, thus promot-
ing  survival  (4).  CpG  DNA-mediated  co-stimulation  in  CD4 
T cells proceeds through the MyD88-dependent PI-3 kinase 
signaling  pathway  (5).  According  to  a  recent  study,  TLR2 
stimulation  activates  Th1  effector  cells  without  TCR  stim-
ulation through the enhanced activation of MAPKs. In con-
trast,  no  TLR  affects  the  function  of  Th2  effector  cells  (6).
    Several studies have reported the co-stimulatory effects of 
TLR on CD8 T cells. TLR2 engagement on CD8 T cells de-
creases the activation threshold for co-stimulatory signals de-
livered by APC (7). Quigley et al. showed that direct TLR2- 
MyD88 signaling in CD8 T cells plays a critical role in clonal 
expansion and memory formation against vaccinia viral (VV) 
infection (8). It has been also reported that MyD88-dependent 
signals are critical for survival of Lymphocytic choriomeningi-
tis virus (LCMV)-specific CD8 T cells and sustained accumu-
lation for viral clearance (9). Furthermore, TLR2 engagement 
on cytotoxic T-lymphocytes (CTL) augments antitumor activity 
against  established  B16  melanoma  tumors  (10).
    Certain  co-stimulatory  molecules  on  activated  T  cells  are 
k n o w n  t o  p r i m a r i l y  b e  i n v o l v e d  i n  e i t h e r  t h e  C D 4  o r  C D 8  
T cell subset. For example, 4-1BB is preferentially involved 
in CD8 T cell-mediated immune responses (11). In the pres-
ent study, we compared the expression and function of TLR2 
on CD4 versus (vs.) CD8 T cells, which have not been di-
rectly compared yet. However, we found that TLR2 co-stim-TLR2 Co-stimulation on CD4 Versus CD8 T Cells
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ulation is more responsible for CD8 T cells than for CD4 T 
cells.
MATERIALS AND METHODS
Mice
Female  B6  (H-2
b)  and  Balb/c  (H-2
d)  mice  were  purchased 
from Orient Bio Inc. (Seoul, Korea). TLR2
-/- (H-2
b) mice were 
provided  by  S.  Akira  (Osaka  University,  Osaka,  Japan).  All 
mice were used for the experiments at the age of 8∼10 weeks.
Antibodies and reagents
The following antibodies were purchased from e-Bioscience 
(San  Diego,  CA)  for  flow  cytometry:  FITC-conjugated  an-
ti-mouse CD3 (145-2C11), TLR2 (6C2), and H-2
b (AF6-88.5); 
PE-conjugated anti-mouse CD4 (GK1.5), CD8 (53-6.7), TLR2 
(6C2), Bcl-2 (3F11), Bcl- xL (7B2.5), and IFN-γ (XMG1.2); 
PE-Cy5-conjugated  anti-mouse  CD4  (GK1.5)  and  CD8  (53- 
6.7);  purified  anti-CD16/32  (2.4G2)  and  purified  anti-TLR2 
(T2.5).  LLO91-99  pentamer  was  obtained  from  ProImmune 
(Oxford, UK). Purified anti-mouse CD3 (145.2C11) was ob-
tained from BD Biosciences (San Jose, CA). Pam 3CSK4 was 
purchased  from  Invivogen  (Carlsbad,  CA).
Cell preparation, culture, and in vitro proliferation 
assay
Naïve T cells were isolated from spleen and lymph nodes of 
B6  using  anti-CD90  (Thy1.2)  magnetic  beads  (Miltenyi 
Biotech, Auburn, CA) after depletion of CD25
+ cells. The cells 
were ＞97% CD3 T cells with a naïve phenotype. To prepare 
the CD4 T and CD8 T cells, CD11c
+ and CD25
+ cells were 
first depleted using anti-CD11c and -CD25 magnetic beads to 
remove Treg and lymphoid dendritic cells and then the cells 
were  isolated  using  anti-CD4  or  -CD8  magnetic  beads, 
respectively.  The  cells  were  ＞97%  CD3
+ C D 4
+ o r  C D 8
+ T  
cells  with  a  naïve  phenotype.  2×10
5  cells  were  stimulated 
with soluble anti-CD3 (0.5 μg/ml) or pulsed with Pam3CSK4 
(2 μg/ml) or LPS (2 μg/ml) for 64 h at 37
oC in a 5% CO2 
environment. Proliferation was measured in triplicate cultures 
by  the  incorporation  of  [
3H]thymidine  (1  μCi/well,  Amers-
ham  Pharmacia)  during  the  last  12  h  of  culture.  The  in-
corporation of [
3H]thymidine was measured with a β-counter 
(Wallac, Torrance, CA). For blocking analysis, purified cells 
were pretreated with anti-TLR2 antibody (2 μg/ml, T2.5) be-
fore  the  stimulation.
In vivo generation of alloantigen activated T cells  
Responder T cells were purified from the spleen and lymph 
nodes of B6 (H-2
b) mice using the anti-CD90 microbead sepa-
ration  system  (Miltenyi  Biotec).  Cells  (1×10
7)  were  sus-
pended in PBS and transferred into lethally irradiated (1,000 
cGy) Balb/c (H-2
d) recipients via tail vein. Recipient spleno-
cytes were isolated at 4 days after transplant, and cells were 
identified as donor T cells with anti-H-2
b and -CD4 or -CD8 
mAb  and  analyzed  by  flow  cytometry.
In vivo generation of Listeria-specific memory CD8 T 
cells
Balb/c mice were infected intravenously (i.v.) with 3000 col-
ony-forming units (CFU) of live L. monocytogenes. On day 
25, the mice were reinfected with 5000 CFU of live bacteria 
intraperitoneally (p. i.); 5 days later, LLO91-99-specific CD8 T 
cells  were  determined  using  LLO91-99 p e n t a m e r .
Flow cytometry
To measure the expression of TLR2, cells were first incubated 
with FcR blocker (2.4G2) to block nonspecific antibody bind-
ing and then stained with PE-anti-TLR2 and PE-Cy5-anti-CD4 
or CD8 and analyzed on a FACSCalibur flow cytometer (BD 
B io sc ie n ce s) u si ng  t h e C el lQ ue st  so ft w are .  To  me as ur e c e ll 
proliferation,  cultured  cells  were  treated  with  BrdU  (2  μg, 
Sigma) for 1 h and washed with PBS. The cells were fixed, 
permeabilized,  treated  with  DNase  I,  and  stained  with 
FITC-anti-BrdU using a BrdU Flow kit according to the manu-
facturer’s  instructions.  To  analyze  cell  death,  cells  were 
stained with FITC-annexin V and 7-AAD. To stain Bcl-2 and 
Bcl-xL, the cells were fixed, permeabilized, and stained with 
PE-anti-Bcl-2  or  -Bcl-xL  mAb.  To  stain  intracellular  IFN-γ, 
cells  were  fixed,  permeabilized  using  the  Cytofix/Cytoperm 
kit  (BD  Bioscience)  according  to  the  manufacturer’s  in-
structions,  and  incubated  with  PE-anti-IFN-γ mAb.
RESULTS
TLR2 expression is preferentially induced on CD8 T 
cells vs. CD4 T cells
To assess  the expression  pattern  of TLR2 on  CD4  vs.  CD8 
T cells, we performed flow cytometric analysis on naïve and 
alloantigen-activated T cells. TLR2 was not expressed on ei-
ther naïve CD4 or CD8 T cells before adoptive transfer into 
allogeneic recipient. Four days after transfer, alloantigen-acti-
vated responder T cells induced TLR 2 expression. However, TLR2 Co-stimulation on CD4 Versus CD8 T Cells
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Figure 1. Expression of TLR2 on CD4 and CD8 T cells. (A) T cells 
were isolated from spleen and lymph nodes of naïve B6 mice as 
described in Materials and Methods and stained with PE-Cy5-anti-CD4
or -CD8 and PE-anti-TLR2, and then analyzed by flow cytometry. The 
cells were adoptively transferred into lethally irradiated (850 cGy) 
Balb/c recipient. Recipient splenocytes were isolated on day 4 and
stained with mAbs against H-2
d, TLR2, and CD4 or CD8. The histo-
gram for TLR2 expression was gated on H-2b
+CD4
+ or H-2b
+CD8
+
cells. (B) Balb/c mice were infected with L. monocytogenes and 
reinfected on day 25 p. i. with 5000 CFU. Splenocytes were isolated
on day 5, stained with FITC-anti-CD8 and PE-LLO91-99 pentamer, and
analyzed by flow cytometry.
Figure 2. TLR2 ligand co-stimulates T cell proliferation in the total T,
CD4, and CD8 T cells. Total T cells were isolated as described in
Materials and Methods and incubated with anti-CD3s in the presence
or absence of TLR2 ligand Pam3CSK4 (PAM) for 64 h. (A) The T cell 
proliferation was determined via [
3H]thymidine incorporation. Values
are means and standard deviations of data from three independent 
experiments. **p＜0.001, anti-CD3 vs. anti-CD3+PAM. (B) Cultured
cells were treated with BrdU (2 μg) for the last 1 h and stained with
PE-anti-CD4 or -CD8 mAb. The cells were then stained for inc-
orporated BrdU and analyzed by flow cytometry. The histogram for
BrdU incorporation was gated on CD4
+ or CD8
+ cells.
the  expression  levels  were  much  higher  on  CD8  T  cells 
(45.7±4.8%)  than  on  CD4  T  cells  (5.4±3.2%)  (Fig.  1A). 
Furthermore,  Listeria-specific  memory  CD8  T  cells  constitu-
tively expressed TLR2 (Fig. 1B). These data indicate that TLR2 
is preferentially expressed on  CD8 T cells following activa-
tion.
TLR2 co-stimulation dominantly enhances CD8 T cell 
expansion more than CD4 T cell expansion 
To test the effect of TLR2 co-stimulation on the proliferation 
of total T cells or CD4 vs. CD8 T cells, T cells were isolated 
a s  d e s c r i b e d  i n  M a t e r i a l s  a n d  M e t h o d s  a n d  i n c u b a t e d  w i t h  
soluble anti-CD3 (anti-CD3s) in the presence or absence of 
TLR2 ligand Pam3CSK4. First, we observed that the co-stim-
ulation of total T cells with Pam3CSK4 led to a seven-fold en-
hancement  of  anti-CD3-induced  proliferation  (Fig.  2A).  We 
next evaluated the ratio of CD4 vs. CD8 T cells in the pro-
liferative capacity of the total T cell population that was en-
hanced by TLR2 co-stimulation, and performed the BrdU in-
corporation assay. Fig. 2B shows that there were more CD8 
T cells than CD4 T cells in the increased proliferative capacity 
of total T cells. To further confirm the direct effect of TLR2 
signaling on T cell subsets, we isolated highly purified pop-
ulations of naïve CD4 or CD8 T cells after the depletion of 
CD11c
+ and CD25
+ cells to remove contaminating lymphoid 
DCs and natural Treg, respectively (＞97% purity). T cell sub-
sets were then incubated with anti-CD3s in the presence or 
absence of Pam3CSK4. The co-stimulation of CD8 T cells with 
Pam3CSK4 led to a 11-fold enhancement of anti-CD3-induced 
proliferation.  However,  the  CD4  cell  proliferation  was  in-TLR2 Co-stimulation on CD4 Versus CD8 T Cells
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Figure 3. Effect of TLR2 co-stimulation on 
proliferation of CD4 T cell vs. CD8 T cells. 
CD4 and CD8 T cells were isolated as 
described in Materials and Methods and 
incubated with anti-CD3s in the presence or 
absence of TLR2 ligand PAM for 64 h. The 
cultured cells were treated with BrdU (2 μg) 
for the last 1 h, stained for incorporated 
BrdU, and analyzed by flow cytometry.
Figure 4. Effect of TLR2 co-stimulation on the
survival of CD4 vs. CD8 T cells. Isolated 
CD4 (A) and CD8 T cells (B) were incubated
with anti-CD3s in the presence or absence of
TLR2 ligand PAM for 64 h. The cells were 
harvested, stained with FITC-Annexin-V and 
7-AAD, and then analyzed by flow cytome-
try. %Survival was determined on annexin 
V-7-AAD-cells. Values are means and stan-
dard deviations of data from three indep-
endent experiments. *p＜0.05, **p＜0.001, 
anti-CD3 vs. anti-CD3+PAM. (C) Cells were
harvested and stained for intracellular Bcl-xL
or Bcl-2.
creased  five-fold  (Fig.  3).  Taken  together,  these  results  in-
dicate  that  TLR2  co-stimulation  is  preferentially  involved  in 
CD8  T  cell  expansion  rather  than  CD4  T  cell  expansion.
TLR2 co-stimulation elevates CD8 T cell survival more 
strongly than CD4 T cell survival 
To further assess the effect of TLR2 co-stimulation on the sur-
vival of CD4 vs. CD8 T cells, isolated naïve CD4 and CD8 
T cells were stimulated with anti-CD3s in the presence or ab-
sence of Pam3CSK4. Survival was then detected by annexin 
V plus 7-AAD staining at 64 h following activation. Pam3CSK4 
increased the activated CD8 T cell survival from 12% to 40% 
(Fig.  4B). However,  the CD4  T cell  survival was  increased 
from 25% to 35% by TLR2 co-stimulation (Fig. 4A). Members 
of the Bcl family are reported to be key mediators of acti-
vated T cell survival following TLR2 co-stimulation (4). There-
fore,  we  compared  the  levels  of  these  molecules  following 
TLR2 ligand treatment of CD4 or CD8 T cells. We observed 
more  significant  increases  in  Bcl-xL  protein  in  Pam3CSK4- 
treated CD8 T cells than in CD4 T cells. However, Bcl-2 pro-
tein levels were similar in CD4 and CD8 T cells (Fig. 4C). 
These data indicate that TLR2 co-stimulation is preferentially TLR2 Co-stimulation on CD4 Versus CD8 T Cells
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Figure 5. Specificity of TLR2 co-stimulation. CD4 and CD8 T cells 
were isolated from normal or TLR2
-/- mice and incubated with 
anti-CD3s in the presence or absence of TLR2 ligand PAM for 64 h.
Other cells were pretreated with purified anti-TLR2 mAb (2 μg/ml) 
before the stimulation. (A) Cultured cells were treated with BrdU (2 
μg) for the last 1 h, stained for incorporated BrdU, and then analyzed 
by flow cytometry. (B) Cultured cells were treated with brefeldin A 
for the last 4 h and stained for intracellular IFN-γ.
involved in CD8 T cell survival versus that in CD4 T cells. 
Thus,  it  is  associated  with  specific  Bcl-xL  up-regulation. 
Specificity of TLR2 co-stimulation
To  exclude  the  possibility  that  the  effects  caused  by 
Pam3CSK4 were non-specific, we tested the assay using an-
ti-TLR2 monoclonal antibody, which was added to the culture 
before the stimulation. As shown in Fig. 5, the enhanced pro-
liferation  with  Pam3CSK4  was  completely  reversed  in  both 
CD4 and CD8 T cells by anti-TLR2 treatment as was IFN-γ 
production. In addition, T cells purified from TLR2
-/- mice ex-
hibited no response to Pam3CSK4 in terms of either the pro-
liferation  (Fig.  5A)  or  the  IFN-γ production  (Fig.  5B),  in-
dicating that Pam3CSK4 acts through TLR2-dependent signal-
ing  pathways.
DISCUSSION
TLR in T cells can function as a co-stimulatory molecule for 
both CD4 and CD8 T cell activation (12). In this study, we 
have confirmed that the TLR2 ligand Pam3CSK4 provides a di-
rect  potent  co-stimulatory  effect  on  TCR-mediated  T  cell 
proliferation.  However,  we  found  that  TLR2  co-stimulation 
was biased toward CD8 T cells rather than CD4 T cells. For 
instance,  the  addition  of  Pam3CSK4 i n c r e a s e d  t h e  a n t i - C D 3 -  
mediated proliferation of total T cells by 7-fold (Fig. 2A). In 
this increased proliferative capacity, CD8 T cells were found 
i n  a  h i g h e r  p r o l i f e r a t i v e  r a t i o  t h a n  C D 4  T  c e l l s  ( F i g .  2 B ) ,  
which was confirmed on an isolated subset of T cells (Fig. 
3). We also observed that TLR2 co-stimulation promoted the 
survival of CD8 T cells more than that of CD4 T cells (Fig. 
4A, B). This was caused not by Bcl-2 but by increased Bcl- 
xL (Fig. 4C). In fact, the different sensitivity to TLR2 co-stim-
ulation is probably related to the expression levels on CD4 
versus CD8 T cells. The surface expression was more highly 
induced following activation on CD8 T cells compared with 
that on CD4 T cells (Fig. 1A). Taken together, these results 
indicate  that  CD8  T  cells  preferentially  respond  to  TLR2 
co-stimulation.
    CD8 T cells are critical for prevention of acute and chronic 
viral infections (13) as well as for tumor eradication (14). In 
recent studies, the physiological significance of TLR2 on CD8 
T cell-mediated effector immune responses has been repor-
ted.  Quigley  et  al.  reported  that  TLR2
-/-  and  MyD88
-/- C D 8  
T cells had severely diminished clonal expansion in response 
to  vaccinia  viral  (VV)  infection,  which  involved  the  TLR2 
co-stimulation on VV-specific CD8 T cells (8). The study also 
reported that long-lived memory CD8 T cells could not devel-
op in the absence of direct TLR2-MyD88 signaling. We also 
observed that TLR2 is constitutively expressed in Listeria-spe-
c i f i c  m e m o r y  C D 8  T  c e l l s  ( F i g .  1 B ) .  I n d e e d ,  r a p i d  L i s t e r i a -  
specific memory CD8 T cell formation is affected by primary 
infection (15). It may be related to TLR2 expression that is 
induced  on  Listeria-specific CD8 T cells during  the primary 
infection  time.  The  TLR2  expression  may  affect  rapid  ex-
pansion of the memory CD8 T cells during the secondary in-
fection  period.
    Our data also indicated that TLR2 co-stimulation decreased 
the threshold for antigen-specific signaling through TCR. We 
stimulated  T  cells  with  soluble  anti-CD3  to  provide  weak 
TCR-mediated  activation.  Although,  under  these  conditions, 
TLR2 signaling effectively elicited the expansion and IFN-γ 
production of CD8 T cells (Fig. 5), it can be speculated that 
TLR2  signaling  affects  autoreactive  CD8  T  cell  responses. 
Autoreactive T cells recognize autoantigens, which are basi-
cally presented by immature DCs that give feeble TCR signal-
ing, resulting in ignorance or anergy (16). Under pathogen 
infection conditions, TLR2 signaling enhances the direct path-TLR2 Co-stimulation on CD4 Versus CD8 T Cells
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way of autoreactive T cell activation by co-stimulation as well 
a s  t h e  i n d i r e c t  p a t h w a y  b y  i n d u c t i o n  o f  D C  m a t u r a t i o n .  A  
number of animal models for autoimmune disease probably 
involve TLR signaling in their pathogenesis (17,18). Our data 
indicate that promoting the expansion and the effector func-
t i o n  o f  C D 8  T  c e l l s  b y  T L R 2  s i g n a l i n g  w a s  c o m p l e t e l y  r e -
versed by the anti-TLR2 mAb, T2.5 (Fig. 5), the therapeutic 
activity of which has been reported in the sepsis model (19). 
Therefore,  T2.5  might  be  become  a  valuable  therapeutic 
agent for CD8 T cell-mediated pathological conditions in the 
presence  of  TLR  ligand.
    Although  it  has  been  recently  suggested  that  TLR2  could 
be  particular  in  its  ability  to  co-stimulate  CD4  and  CD8  T 
cells, in this present study, we find that its dominant effect 
appears to be the regulation of CD8 T cell activation. These 
observations suggest a potential therapeutic role for this mol-
ecule in the management of cancer and chronic infectious dis-
eases  as  well  as  autoimmune  diseases. 
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